SCHEMBL10063187

SCHEMBL10063187

CCOc1ccc(NC(=O)c2cc(-c3ccncc3)c[nH]c2=O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 2/20 0.61
▸ ITK Q08881 2/20 0.60
▸ KMT2A Q03164 4/20 0.58
▸ LMNA P02545 3/20 0.55
▸ RAB9A P51151 5/20 0.52
▸ NPC1 O15118 4/20 0.52
▸ SMN1; SMN2 Q16637 4/20 0.52
▸ POLB P06746 2/20 0.52
▸ TP53 P04637 2/20 0.52
▸ KDM4E B2RXH2 3/20 0.51
▸ MITF O75030 1/20 0.51
▸ PKM P14618 1/20 0.51
▸ MEN1 O00255 3/20 0.51
▸ TTK P33981 1/20 0.51
▸ AURKB Q96GD4 1/20 0.51
▸ INCENP Q9NQS7 1/20 0.51
▸ MAPT P10636 4/20 0.49
▸ GAA P10253 2/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ ALOX15 P16050 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10063120 0.88 ITK (0.64) ALKITKKMT2ALMNARAB9A
SCHEMBL10063111 0.85 ALK (0.70) ALKITKRAB9ANPC1TTK
SCHEMBL10063117 0.83 ITK (0.61) ALKITKKMT2ARAB9ANPC1
SCHEMBL10063116 0.82 ITK (0.67) ALKITKKMT2ALMNARAB9A
SCHEMBL15850171 0.81 ITK (0.67) ALKITKKMT2ALMNASMN1; SMN2
SCHEMBL10063126 0.81 ITK (0.67) ALKITKTTKAURKBINCENP
SCHEMBL10063128 0.81 ITK (0.64) ALKITKRAB9ANPC1SMN1; SMN2
SCHEMBL10063131 0.79 ITK (0.59) ALKITKKMT2ALMNARAB9A
SCHEMBL10063134 0.78 TTK (0.64) ALKITKKMT2ARAB9ANPC1
SCHEMBL10063192 0.78 ALK (0.58) ALKITKLMNARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1831168-B1 PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY PROTEIN KINASES FOR THE TREATMENT OF INFLAMMATORY, PROLIFERATIVE AND IMMUNOLOGICALLY-MEDIATED DISEASES. VERTEX PHARMA (US) 2014-07-02 — — EP disclosed
US-20130184259-A1 PYRIDONES USEFUL AS INHIBITORS OF KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-18 — — US disclosed
US-8338597-B2 Pyridones useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-25 — — US disclosed
US-8338597-B2 Pyridones useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-25 — — US disclosed
US-20120190699-A1 PYRIDONES USEFUL AS INHIBITORS OF KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-26 — — US disclosed
US-20120190699-A1 PYRIDONES USEFUL AS INHIBITORS OF KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-26 — — US disclosed
US-8101770-B2 Pyridones useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-01-24 — — US disclosed
US-8101770-B2 Pyridones useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-01-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190699-A1 PYRIDONES USEFUL AS INHIBITORS OF KINASES MAP3K20, MAP3K6, MAP3K5 ALK 581/4885ITK 393/4885KMT2A 1428/4885
US-20130184259-A1 PYRIDONES USEFUL AS INHIBITORS OF KINASES MAP3K20, MAP3K6, MAP3K5 ALK 581/4885ITK 393/4885KMT2A 1428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback